

# Stefano Aliberti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2437637/publications.pdf>

Version: 2024-02-01

379  
papers

16,104  
citations

22153

59  
h-index

22166

113  
g-index

390  
all docs

390  
docs citations

390  
times ranked

18979  
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection and Classification of Bronchiectasis Through Convolutional Neural Networks. <i>Journal of Thoracic Imaging</i> , 2022, 37, 100-108.	1.5	9
2	Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 111-114.	0.7	25
3	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. <i>Lancet Respiratory Medicine</i> , 2022, 10, 298-306.	10.7	70
4	Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 977.	4.1	14
5	Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease. <i>Chest</i> , 2022, 162, 76-81.	0.8	14
6	Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 894-902.	5.6	67
7	Predictors of Helmet CPAP Failure in COVID-19 Pneumonia: A Prospective, Multicenter, and Observational Cohort Study. <i>Canadian Respiratory Journal</i> , 2022, 2022, 1-6.	1.6	11
8	Safety and feasibility of physiotherapy in ICU-admitted severe COVID-19 patients: an observational study. <i>Monaldi Archives for Chest Disease</i> , 2022, , .	0.6	3
9	Comparison of different sets of immunological tests to identify treatable immunodeficiencies in adult bronchiectasis patients. <i>ERJ Open Research</i> , 2022, 8, 00388-2021.	2.6	3
10	Leveraging the Omics Revolution for Nontuberculous Mycobacteria Biomarkers. <i>Chest</i> , 2022, 161, 1129-1131.	0.8	0
11	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2022, 60, 2200803.	6.7	22
12	World Bronchiectasis Day 2022. <i>European Respiratory Journal</i> , 2022, 59, 2201249.	6.7	3
13	Chest X-ray findings in a large cohort of 1117 patients with SARS-CoV-2 infection: a multicenter study during COVID-19 outbreak in Italy. <i>Internal and Emergency Medicine</i> , 2021, 16, 1173-1181.	2.0	12
14	Management of Drug Toxicity in <i>Mycobacterium avium</i> Complex Pulmonary Disease: An Expert Panel Survey. <i>Clinical Infectious Diseases</i> , 2021, 73, e256-e259.	5.8	16
15	Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. <i>Chest</i> , 2021, 159, 58-72.	0.8	24
16	Baseline Cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 388-394.	0.7	21
17	The ADAMTS13 von Willebrand factor axis in COVID-19 patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 513-521.	3.8	176
18	Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 561-566.e4.	2.9	90

#	ARTICLE	IF	CITATIONS
19	A Cluster Analysis of Bronchiectasis Patients Based on the Airway Immune Profile. <i>Chest</i> , 2021, 159, 1758-1767.	0.8	18
20	Response. <i>Chest</i> , 2021, 159, 1677-1678.	0.8	0
21	Lung Recruitability of COVID-19 Pneumonia in Patients Undergoing Helmet CPAP. <i>Archivos De Bronconeumologia</i> , 2021, 57, 92-94.	0.8	10
22	Nasopharyngeal Microbiota Analysis in Healthy and Otitis-prone Children. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 16-21.	2.0	10
23	Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 419-424.	2.5	9
24	Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound?. <i>Journal of Ultrasound</i> , 2021, 24, 165-173.	1.3	16
25	Hemostatic alterations in COVID-19. <i>Haematologica</i> , 2021, 106, 1472-1475.	3.5	34
26	Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables. <i>Radiologia Medica</i> , 2021, 126, 722-728.	7.7	31
27	Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. <i>Internal and Emergency Medicine</i> , 2021, 16, 1223-1229.	2.0	31
28	Nontuberculous mycobacterial pulmonary disease: an integrated approach beyond antibiotics. <i>ERJ Open Research</i> , 2021, 7, 00574-2020.	2.6	20
29	Assessment of Platelet Thrombus Formation under Flow Conditions in Adult Patients with COVID-19: An Observational Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1087-1096.	3.4	9
30	Respiratory Mycoses in COPD and Bronchiectasis. <i>Mycopathologia</i> , 2021, 186, 623-638.	3.1	15
31	Never Let a Good Crisis Go to Waste. <i>Chest</i> , 2021, 159, 917-919.	0.8	5
32	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2021, 57, 2100048.	6.7	152
33	Elexacaftorâ€“tezacaftorâ€“ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation. <i>Current Opinion in Pharmacology</i> , 2021, 57, 81-88.	3.5	12
34	Integrative microbiomics in bronchiectasis exacerbations. <i>Nature Medicine</i> , 2021, 27, 688-699.	30.7	105
35	Predictors of starting antimicrobial treatment in patients with nontuberculous mycobacterial lung disease in the Italian scenario: A SITA GIOVANI-IRENE promoted web-survey. <i>Respiratory Medicine</i> , 2021, 179, 106341.	2.9	2
36	SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. <i>Respiratory Medicine</i> , 2021, 180, 106355.	2.9	25

#	ARTICLE	IF	CITATIONS
37	Prevalence and serotyping of <i>S. pneumoniae</i> in a large vaccine-naïve cohort of adults with cystic fibrosis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2443-2446.	2.9	0
38	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 522-532.	10.7	195
39	Protease “Antiprotease Imbalance in Bronchiectasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5996.	4.1	17
40	Prognostic parameters of in-hospital mortality in COVID-19 patients: An Italian experience. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13629.	3.4	31
41	Noninvasive Ventilatory Support of Patients with COVID-19 outside the Intensive Care Units (WARD-COVID). <i>Annals of the American Thoracic Society</i> , 2021, 18, 1020-1026.	3.2	111
42	Response. <i>Chest</i> , 2021, 159, 2507-2508.	0.8	0
43	Patients’ perspectives on Bronchiectasis: findings from a social media listening (SML) study. <i>ERJ Open Research</i> , 2021, 7, 00096-2021.	2.6	6
44	T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis. <i>Biomedicines</i> , 2021, 9, 772.	3.2	24
45	Diagnosis and Initial Investigation of Bronchiectasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 513-524.	2.1	4
46	Noninvasive respiratory support outside the intensive care unit for acute respiratory failure related to coronavirus-19 disease: a systematic review and meta-analysis. <i>Critical Care</i> , 2021, 25, 268.	5.8	56
47	Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19. <i>Science Immunology</i> , 2021, 6, .	11.9	108
48	Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 873-884.	10.7	99
49	ROSE: radiology, obstruction, symptoms and exposure – a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. <i>ERJ Open Research</i> , 2021, 7, 00399-2021.	2.6	19
50	Small Airway Disease and Emphysema Are Associated with Future Exacerbations in Smokers with CT-derived Bronchiectasis and COPD: Results from the COPD Gene Cohort. <i>Radiology</i> , 2021, 300, 706-714.	7.3	16
51	Community-acquired pneumonia. <i>Lancet</i> , 2021, 398, 906-919.	13.7	82
52	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology</i> , 2021, 3, e690-e697.	3.9	121
53	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1316-1325.	3.2	6
54	The Isoform GC1f of the Vitamin D Binding Protein Is Associated with Bronchiectasis Severity. <i>Biomedicines</i> , 2021, 9, 1573.	3.2	3

#	ARTICLE	IF	CITATIONS
55	What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey. <i>ERJ Open Research</i> , 2021, 7, 00807-2020.	2.6	8
56	Bronchiectasis as a Long-Term Consequence of SARS-COVID-19 Pneumonia: Future Studies are Needed. <i>Archivos De Bronconeumologia</i> , 2021, 57, 739-740.	0.8	10
57	Exosomes Recovered From the Plasma of COVID-19 Patients Expose SARS-CoV-2 Spike-Derived Fragments and Contribute to the Adaptive Immune Response. <i>Frontiers in Immunology</i> , 2021, 12, 785941.	4.8	38
58	COVID-19 in Immunocompromised Patients: A Systematic Review. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 839-858.	2.1	7
59	HDL in COVID-19 Patients: Evidence from an Italian Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5955.	2.4	9
60	Respiratory failure in COVID-19: a patient's perspective and clinical cases. , 2021, , 1-13.		0
61	Post-COVID-19 sequelae. , 2021, , 180-196.		4
62	Prevalence and risk factors for <i>Enterobacteriaceae</i> in patients hospitalized with community-acquired pneumonia. <i>Respirology</i> , 2020, 25, 543-551.	2.3	31
63	Oral Corticosteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). <i>World Allergy Organization Journal</i> , 2020, 13, 100464.	3.5	30
64	Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106184.	2.5	48
65	Prone and Lateral Positioning in Spontaneously Breathing Patients With COVID-19 Pneumonia Undergoing Noninvasive Helmet CPAP Treatment. <i>Chest</i> , 2020, 158, 2431-2435.	0.8	56
66	COVID-19 in pregnant women: A systematic review and meta-analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 252, 543-558.	1.1	95
67	Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy. <i>Respiratory Medicine</i> , 2020, 175, 106204.	2.9	17
68	2019 ATS/IDSA CRITERIA TO IDENTIFY P. AERUGINOSA AND MRSA PROMOTE OVERUTILIZATION OF MRSA THERAPY IN NON-SEVERE CAP. <i>Chest</i> , 2020, 157, A91.	0.8	0
69	Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study. <i>European Respiratory Journal</i> , 2020, 56, 2001935.	6.7	117
70	Diagnosis and quantification of bronchiectasis using computed tomography or magnetic resonance imaging: A systematic review. <i>Respiratory Medicine</i> , 2020, 170, 105954.	2.9	16
71	Repeatability of Circulating Eosinophil Measures and Inhaled Corticosteroids Effect in Bronchiectasis. A Post Hoc Analysis of a Randomized Clinical Trial. <i>Archivos De Bronconeumologia</i> , 2020, 56, 681-683.	0.8	23
72	YOU DON'T FIND WHAT YOU DON'T LOOK FOR: PREVALENCE OF IMMUNODEFICIENCY IN PATIENTS WITH CYSTIC FIBROSIS USING A BROAD IMMUNOLOGICAL SCREENING. <i>Chest</i> , 2020, 157, A90.	0.8	0

#	ARTICLE	IF	CITATIONS
73	COVID-19 multidisciplinary high dependency unit: the Milan model. <i>Respiratory Research</i> , 2020, 21, 260.	3.6	22
74	Blood eosinophils do not predict inhaled budesonide response in bronchiectasis. <i>European Respiratory Journal</i> , 2020, 56, 2002210.	6.7	7
75	Upper Respiratory Tract Microbiome and Otitis Media Intertalk: Lessons from the Literature. <i>Journal of Clinical Medicine</i> , 2020, 9, 2845.	2.4	11
76	The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2943.	2.4	17
77	From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5882.	4.1	57
78	International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline. <i>Chest</i> , 2020, 158, 1912-1918.	0.8	26
79	Pharmacotherapeutic management of bronchial infections in adults: non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1975-1990.	1.8	4
80	Early Phases of COVID-19 Are Characterized by a Reduction in Lymphocyte Populations and the Presence of Atypical Monocytes. <i>Frontiers in Immunology</i> , 2020, 11, 560330.	4.8	47
81	Role of inhaled corticosteroids in reducing exacerbations in bronchiectasis patients with blood eosinophilia pooled post-hoc analysis of 2 randomized clinical trials. <i>Respiratory Medicine</i> , 2020, 172, 106127.	2.9	24
82	A pathway to keep all lifelong learners up to date: the ERS continuing professional development programme. <i>European Respiratory Journal</i> , 2020, 55, 1902425.	6.7	2
83	Complement activation in patients with COVID-19: A novel therapeutic target. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 215-217.	2.9	210
84	Pulmonary fibrosis secondary to COVID-19: a call to arms?. <i>Lancet Respiratory Medicine</i> , 2020, 8, 750-752.	10.7	404
85	Blood eosinophils predict inhaled fluticasone response in bronchiectasis. <i>European Respiratory Journal</i> , 2020, 56, 2000453.	6.7	38
86	Serum Desmosine Is Associated with Long-Term All-Cause and Cardiovascular Mortality in Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 897-899.	5.6	14
87	The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients. <i>European Respiratory Journal</i> , 2020, 56, 2001157.	6.7	43
88	Use of anakinra in severe COVID-19: A case report. <i>International Journal of Infectious Diseases</i> , 2020, 96, 607-609.	3.3	58
89	Sputum neutrophil elastase associates with microbiota and <i>Pseudomonas aeruginosa</i> in bronchiectasis. <i>European Respiratory Journal</i> , 2020, 56, 2000769.	6.7	37
90	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020, 383, 1522-1534.	27.0	1,548

#	ARTICLE	IF	CITATIONS
91	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults. <i>Chest</i> , 2020, 158, 1896-1911.	0.8	105
92	COVID-19 in lung transplant recipients: A case series from Milan, Italy. <i>Transplant Infectious Disease</i> , 2020, 22, e13356.	1.7	19
93	Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1499-1507.	5.6	25
94	Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study. <i>European Respiratory Journal</i> , 2020, 56, 2001702.	6.7	15
95	Real-life evaluation of clinical outcomes in patients undergoing treatment for non-tuberculous mycobacteria lung disease: A ten-year cohort study. <i>Respiratory Medicine</i> , 2020, 164, 105899.	2.9	16
96	Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST). <i>Respiratory Research</i> , 2020, 21, 18.	3.6	11
97	Prevalence and incidence of bronchiectasis in Italy. <i>BMC Pulmonary Medicine</i> , 2020, 20, 15.	2.0	36
98	Sympatho-Vagal Dysfunction in Patients with End-Stage Lung Disease Awaiting Lung Transplantation. <i>Journal of Clinical Medicine</i> , 2020, 9, 1146.	2.4	10
99	A Systematic Review of the Effect of Delayed Appropriate Antibiotic Treatment on the Outcomes of Patients With Severe Bacterial Infections. <i>Chest</i> , 2020, 158, 929-938.	0.8	46
100	Desmosine is a predictor of long-term cardiovascular mortality in bronchiectasis. , 2020, , .		1
101	Cardiovascular side-effects of common antibiotics. , 2020, , 264-278.		1
102	Salivary SLPI and disease severity in bronchiectasis. , 2020, , .		0
103	Airway clearance techniques in patients with bronchiectasis. Data from the EMBARC Registry. , 2020, , .		3
104	A First Look at the Italian Registry on Pulmonary Non-Tuberculous Mycobacteria (NTM) -IRENE. , 2020, , .		0
105	Novel <i>Pseudomonas aeruginosa</i> scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumonia. , 2020, , .		0
106	Epidemiology and factors associated with overweight in adults with cystic fibrosis: an Italian multicenter experience. , 2020, , .		0
107	Asthma as a co-morbidity and cause of bronchiectasis: data from the European Bronchiectasis Registry (EMBARC). , 2020, , .		0
108	Neutrophil elastase is correlated with disease severity in a cohort from Southern Europe. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
109	International Guideline concordance of empiric antibiotic use in community-acquired pneumonia. , 2020, , .		0
110	The Relationship Between Symptoms, Exacerbations And Treatment Response in Bronchiectasis. , 2020, , .		0
111	Impact of cough on insomnia and sleep quality in bronchiectasis. , 2020, , .		1
112	Endotyping bronchiectasis through multi-omic profiling. , 2020, , .		0
113	Immunodeficiency associated bronchiectasis in the European Bronchiectasis Registry (EMBARC). , 2020, , .		0
114	Bronchiectasis in Italy: data from the national registry IRIDE. , 2020, , .		0
115	Whatâ€™s important for people with NTM? An EMBARC-ELF patient survey. , 2020, , .		1
116	Placebo effects in pharmaceutical clinical trials in bronchiectasis: an EMBARC study. , 2020, , .		1
117	Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia. , 2020, , .		0
118	Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia. , 2020, , .		0
119	Sex related differences in aetiology, severity and quality of life in bronchiectasis: data from the EMBARC, EMBARC-India and Australian bronchiectasis registries. , 2020, , .		0
120	Alpha-1 antitrypsin deficiency in patients with bronchiectasis: data from the European Bronchiectasis Registry EMBARC. , 2020, , .		0
121	Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. Clinical Infectious Diseases, 2019, 68, 1482-1493.	5.8	116
122	Administrative databases and clinical governance: The case of COPD. International Journal of Health Planning and Management, 2019, 34, 177-186.	1.7	2
123	Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. The Lancet Global Health, 2019, 7, e1269-e1279.	6.3	116
124	Prevalence, risk factors and outcomes of patients coming from the community with sepsis due to multidrug resistant bacteria. Multidisciplinary Respiratory Medicine, 2019, 14, 23.	1.5	23
125	Antimicrobial peptides, disease severity and exacerbations in bronchiectasis. Thorax, 2019, 74, 835-842.	5.6	43
126	International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia. Journal of Infection, 2019, 79, 300-311.	3.3	36



#	ARTICLE	IF	CITATIONS
127	In Vitro Synergism of Colistin and N-acetylcysteine against <i>Stenotrophomonas maltophilia</i> . <i>Antibiotics</i> , 2019, 8, 101.	3.7	22
128	Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 59, 101856.	2.6	16
129	MULTI-DRUG RESISTANT PATHOGEN SCORES PROMOTE THE OVERUSE OF ANTI-PSEUDOMONAS ANTIBIOTICS. <i>Chest</i> , 2019, 156, A1125.	0.8	1
130	QuantIFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. <i>Journal of Infection</i> , 2019, 79, 444-453.	3.3	64
131	Management of Acute Respiratory Failure Due to Community-Acquired Pneumonia: A Systematic Review. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 10.	2.9	11
132	A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation. <i>European Respiratory Journal</i> , 2019, 53, 1900303.	6.7	50
133	Comparison of different conditions for DNA extraction in sputum - a pilot study. <i>Multidisciplinary Respiratory Medicine</i> , 2019, 14, 6.	1.5	14
134	A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults. <i>European Respiratory Review</i> , 2019, 28, 180108.	7.1	21
135	National Survey on the Management of Adult Bronchiectasis in Belgium. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 72-74.	1.6	5
136	Shadow cost of oral corticosteroids-related adverse events: A pharmaco-economic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. <i>World Allergy Organization Journal</i> , 2019, 12, 100007.	3.5	82
137	Continuous professional development: elevating thoracic oncology education in Europe. <i>Breathe</i> , 2019, 15, 279-285.	1.3	0
138	The biology of pulmonary exacerbations in bronchiectasis. <i>European Respiratory Review</i> , 2019, 28, 190055.	7.1	48
139	An international perspective on hospitalized patients with viral community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2019, 60, 54-70.	2.2	26
140	Pneumonia is a neglected problem: it is now time to act. <i>Lancet Respiratory Medicine</i> , 2019, 7, 10-11.	10.7	22
141	Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 525-529.	0.7	43
142	Non-invasive positive pressure ventilation in pneumonia outside Intensive Care Unit: An Italian multicenter observational study. <i>European Journal of Internal Medicine</i> , 2019, 59, 21-26.	2.2	18
143	A point of care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation. , 2019, , .		4
144	Determinants of survival in the European Bronchiectasis Registry(EMBARC). , 2019, , .		1

#	ARTICLE	IF	CITATIONS
145	Inflammatory molecular endotypes in bronchiectasis. , 2019, , .		5
146	Respiratory viruses in stable state bronchiectasis. , 2019, , .		1
147	Heparin Binding Protein in sputum compromises epithelial defence and relates to bronchiectasis severity. , 2019, , .		1
148	New isolation of non-tuberculous mycobacteria in patients with bronchiectasis - data from the European Bronchiectasis Registry (EMBARC). , 2019, , .		1
149	Prevalence of <i>S. pneumoniae</i> colonization and serotypes in sputum of vaccine-naïve adults with cystic fibrosis. , 2019, , .		0
150	Risk factors for new <i>P. aeruginosa</i> isolation in bronchiectasis- data from the European Bronchiectasis Registry (EMBARC). , 2019, , .		1
151	<i>S. pneumoniae</i> prevalence and serotypes in sputum of stable bronchiectasis. , 2019, , .		0
152	A broad immunological screening may impact treatment in bronchiectasis patients. , 2019, , .		0
153	Outcomes of patients undergoing treatment for non-tuberculous mycobacteria lung disease. , 2019, , .		0
154	MRSA specific scores promote overuse of anti-MRSA antibiotics. , 2019, , .		0
155	Respiratory viruses in adults with cystic fibrosis during stable and exacerbations. , 2019, , .		0
156	Management of respiratory outpatients: A retrospective descriptive analysis. , 2019, , .		0
157	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017Âupdate. European Respiratory Journal, 2018, 51, 1702678.	6.7	50
158	Nosocomial transmission of carbapenem-resistant <i>Klebsiella pneumoniae</i> in an Italian university hospital: a molecular epidemiological study. Journal of Hospital Infection, 2018, 99, 413-418.	2.9	48
159	Prognostic and Pathogenic Role of Angiopoietin-1 and -2 in Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 220-231.	5.6	58
160	The independent contribution of <i>Pseudomonas aeruginosa</i> infection to long-term clinical outcomes in bronchiectasis. European Respiratory Journal, 2018, 51, 1701953.	6.7	150
161	Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network. European Respiratory Journal, 2018, 51, 1701937.	6.7	23
162	Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1410-1420.	5.6	215

#	ARTICLE	IF	CITATIONS
163	The BRICS (Bronchiectasis Radiologically Indexed CT Score). <i>Chest</i> , 2018, 153, 1177-1186.	0.8	44
164	ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training. <i>Breathe</i> , 2018, 14, 269-275.	1.3	1
165	Cardiovascular Autonomic Control in End Stage Lung Disease Before Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, S457-S458.	0.6	0
166	A comprehensive approach to lung function in bronchiectasis. <i>Respiratory Medicine</i> , 2018, 145, 120-129.	2.9	46
167	A real life evaluation of non invasive ventilation in acute cardiogenic pulmonary edema: a multicenter, perspective, observational study for the ACPE SIMEU study group. <i>BMC Emergency Medicine</i> , 2018, 18, 61.	1.9	11
168	Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective. <i>BMC Infectious Diseases</i> , 2018, 18, 677.	2.9	34
169	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) ERS Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2018, 52, 1802074.	6.7	26
170	In vitro activity of N-acetylcysteine against <i>Stenotrophomonas maltophilia</i> and <i>Burkholderia cepacia</i> complex grown in planktonic phase and biofilm. <i>PLoS ONE</i> , 2018, 13, e0203941.	2.5	29
171	Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis. <i>Respiratory Research</i> , 2018, 19, 205.	3.6	18
172	Research Needs on Respiratory Health in Migrant and Refugee Populations. An Official American Thoracic Society and European Respiratory Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1247-1255.	3.2	6
173	How to Process Sputum Samples and Extract Bacterial DNA for Microbiota Analysis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3256.	4.1	28
174	Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study. <i>ERJ Open Research</i> , 2018, 4, 00096-2018.	2.6	28
175	Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. <i>Multidisciplinary Respiratory Medicine</i> , 2018, 13, 39.	1.5	17
176	Get together to increase awareness in bronchiectasis: a report of the 2nd World Bronchiectasis Conference. <i>Multidisciplinary Respiratory Medicine</i> , 2018, 13, 28.	1.5	4
177	When and how ruling out cystic fibrosis in adult patients with bronchiectasis. <i>Multidisciplinary Respiratory Medicine</i> , 2018, 13, 29.	1.5	8
178	In vitro synergism of colistin in combination with N-acetylcysteine against <i>Acinetobacter baumannii</i> grown in planktonic phase and in biofilms. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2388-2395.	3.0	19
179	The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. <i>European Respiratory Journal</i> , 2018, 52, 1800328.	6.7	138
180	Burden and risk factors for <i>Pseudomonas aeruginosa</i> community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. <i>European Respiratory Journal</i> , 2018, 52, 1701190.	6.7	122

#	ARTICLE	IF	CITATIONS
181	The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. Multidisciplinary Respiratory Medicine, 2018, 13, 33.	1.5	10
182	Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis. Multidisciplinary Respiratory Medicine, 2018, 13, 26.	1.5	27
183	Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. Respiratory Medicine, 2018, 140, 115-121.	2.9	11
184	An extensive bundle of tests is needed to detect treatable causes of bronchiectasis (Bx). , 2018, , .		1
185	Antimicrobial peptides and airway bacterial colonization in bronchiectasis. , 2018, , .		2
186	Determinants of quality of life in bronchiectasis using the quality of life bronchiectasis (QOL-B) questionnaire: data from the EMBARC registry. , 2018, , .		3
187	The heterogeneity of bronchiectasis patient characteristics, management and outcomes across Europe: Data from the EMBARC registry. , 2018, , .		4
188	Impact of Inflammatory bowel disease in bronchiectasis (IBD-BR) data from the EMBARC registry. , 2018, , .		1
189	Characteristics of patients with pulmonary non-tuberculous Mycobacterial infection in bronchiectasis: Data from the EMBARC registry. , 2018, , .		3
190	What is the best technique to extract bacterial DNA from sputum?. , 2018, , .		1
191	Development of antibiotic-resistance in P. aeruginosa obtained from bronchiectasis patients: a multicenter prospective observational study. , 2018, , .		1
192	Impact of bronchiectasis on severe asthma: data from the "Severe Asthma Network Italy"(SANI) registry. , 2018, , .		1
193	Positive end expiratory pressure in acute hypoxemic respiratory failure due to community acquired pneumonia: do we need a personalized approach?. Peerj, 2018, 6, e4211.	2.0	8
194	Rhinosinusitis is associated with increased symptoms and more frequent exacerbations among patients with bronchiectasis- data from the EMBARC registry. , 2018, , .		1
195	Risk factors for immunosuppression in hospitalized patients coming from the community with pneumonia: a worldwide perspective. , 2018, , .		0
196	How to diagnose and quantify bronchiectasis for clinical studies using chest imaging. , 2018, , .		0
197	Chest Physiotherapy in patients with Bronchiectasis " what is the current practice in Europe?. , 2018, , .		0
198	Sputum glucose as a marker of disease severity in adult patients with cystic fibrosis. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
199	Comparison of bronchiectasis cohorts from tertiary centres in Sydney, Milan and Dundee reveal differences in severity and patterns of care. , 2018, , .		0
200	Validation of the Italian version of Bronchiectasis Quality of Life Questionnaire (QoL-B). , 2018, , .		0
201	Synergistic activity of colistin in combination with N-acetylcysteine against colistin-resistant <i>Acinetobacter Baumannii</i> grown in biofilms. , 2018, , .		0
202	Clinical characteristics and disease severity of adults with cystic fibrosis with at least one residual function mutation. , 2018, , .		0
203	Validity of COPD diagnosis in Bronchiectasis patients: data from the EMBARC registry. , 2018, , .		0
204	Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE). , 2018, , .		0
205	Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation. , 2018, , .		0
206	In vitro activity of colistin in combination with N-acetylcysteine against <i>Pseudomonas aeruginosa</i> . , 2018, , .		0
207	ERS guideline compliant antibiotics among hospitalized patients with Community-acquired pneumonia on the ward service. , 2018, , .		0
208	Cardiovascular Autonomic Control in Lung Transplantation Recipients. , 2018, , .		0
209	Additional important research priorities for bronchiectasis in China. <i>European Respiratory Journal</i> , 2017, 49, 1602317.	6.7	0
210	Investigating the Etiology of Bronchiectasis: You Do Not Find What You Do Not Look For. <i>Respiration</i> , 2017, 93, 228-229.	2.6	10
211	Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent Risk Factor for Mortality in Patients With Bronchiectasis. <i>Chest</i> , 2017, 151, 1247-1254.	0.8	81
212	Epidemiology of clinical trials of medicines in respiratory diseases in Europe and Italy. <i>Respiratory Medicine</i> , 2017, 125, 8-11.	2.9	2
213	An update on the pharmacotherapeutic management of lower respiratory tract infections. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 973-988.	1.8	9
214	Selection of Candidates for Lung Transplantation: The First Italian Consensus Statement. <i>Transplantation Proceedings</i> , 2017, 49, 702-706.	0.6	7
215	Standard operating procedures for tuberculosis care. <i>European Respiratory Journal</i> , 2017, 49, 1700515.	6.7	6
216	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. <i>European Respiratory Journal</i> , 2017, 49, 1700051.	6.7	253

#	ARTICLE	IF	CITATIONS
217	Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 609-620.	5.6	120
218	Beyond pulmonary nontuberculous mycobacteria disease: do extra-pulmonary forms represent an emerging clinical and public health threat?. ERJ Open Research, 2017, 3, 00091-2017.	2.6	5
219	Role of <i>Streptococcus pneumoniae</i> infection in chronic obstructive pulmonary disease patients in Italy. Therapeutic Advances in Respiratory Disease, 2017, 11, 403-407.	2.6	12
220	Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia. European Respiratory Journal, 2017, 50, 1602306.	6.7	5
221	European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal, 2017, 50, 1700629.	6.7	788
222	The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration. Breathe, 2017, 13, 180-192.	1.3	34
223	Respiratory research networks in Europe and beyond: aims, achievements and aspirations for the 21st century. Breathe, 2017, 13, 209-215.	1.3	2
224	Risk Factors for Noninvasive Ventilation Failure in Critically Ill Subjects With Confirmed Influenza Infection. Respiratory Care, 2017, 62, 1307-1315.	1.6	59
225	Serotypes and antibiotic susceptibility of <i>Streptococcus pneumoniae</i> isolated from hospitalized patients with community-acquired pneumonia in Italy. SAGE Open Medicine, 2017, 5, 205031211772005.	1.8	7
226	Standardised classification of the aetiology of bronchiectasis using an objective algorithm. European Respiratory Journal, 2017, 50, 1701289.	6.7	63
227	Intensive care unit patients with lower respiratory tract nosocomial infections: the ENIRRI project. ERJ Open Research, 2017, 3, 00092-2017.	2.6	22
228	High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis. European Respiratory Journal, 2017, 50, 1700013.	6.7	9
229	Individualizing duration of antibiotic therapy in community-acquired pneumonia. Pulmonary Pharmacology and Therapeutics, 2017, 45, 191-201.	2.6	13
230	A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis. Lung, 2017, 195, 679-682.	3.3	10
231	Bronchiectasis and <i>Aspergillus</i> : How are they linked?. Medical Mycology, 2017, 55, 69-81.	0.7	35
232	Prevalence and Risk Factors for Enterobacteriaceae (EB) and Multidrug-Resistant EB in Community-Acquired Pneumonia. Chest, 2017, 152, A156.	0.8	1
233	Anti-MRSA Coverage Overutilization as Empiric Therapy for Hospitalized Patients With Community-Acquired Pneumonia and Healthcare-Associated Pneumonia. Chest, 2017, 152, A157.	0.8	1
234	Anaerobic Coverage is Not Needed for Patients With Chronic Aspiration Hospitalized With Community-Acquired Pneumonia. Chest, 2017, 152, A152.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Neutrophil elastase in bronchiectasis. <i>Respiratory Research</i> , 2017, 18, 211.	3.6	75
236	Phenotype characterization of non-cystic fibrosis bronchiectasis in India. , 2017, , .		1
237	Chest physiotherapy in European patients with bronchiectasis: Data from the EMBARC registry. , 2017, , .		3
238	The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis. <i>Annals of Thoracic Medicine</i> , 2017, 12, 135.	1.8	37
239	Using cluster analysis of cytokines to identify patterns of inflammation in hospitalized patients with community-acquired pneumonia: a pilot study.. <i>The University of Louisville Journal of Respiratory Infections</i> , 2017, 1, 3-11.	0.0	13
240	The association between gastro-oesophageal reflux and exacerbations of bronchiectasis: data from the EMBARC registry. , 2017, , .		0
241	Late Breaking Abstract - The prevalence and burden of <i>Pseudomonas aeruginosa</i> among bronchiectasis patients in Europe- data from the FRIENDS cohort. , 2017, , .		0
242	Non-Intensive Care Unit Acquired Pneumonia: A New Clinical Entity?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 287.	4.1	29
243	Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1913.	4.1	70
244	Quality standards for the management of bronchiectasis in Italy: a national audit. <i>European Respiratory Journal</i> , 2016, 48, 244-248.	6.7	33
245	Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. <i>Thorax</i> , 2016, 71, 1110-1118.	5.6	128
246	Serum and exhaled breath condensate inflammatory cytokines in community-acquired pneumonia: a prospective cohort study. <i>Pneumonia (Nathan Qld)</i> , 2016, 8, 8.	6.1	11
247	The ERS Research Agency: the beginning. <i>European Respiratory Journal</i> , 2016, 47, 1017-1023.	6.7	13
248	Clinical phenotypes in bronchiectasis: right on track to develop precision medicine in respiratory diseases. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 709-709.	1.2	1
249	The best of respiratory infections from the 2015 European Respiratory Society International Congress. <i>ERJ Open Research</i> , 2016, 2, 00049-2016.	2.6	0
250	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. <i>Cytokine</i> , 2016, 88, 267-273.	3.2	54
251	Characterization of bronchiectasis in the elderly. <i>Respiratory Medicine</i> , 2016, 119, 13-19.	2.9	28
252	Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices. <i>European Respiratory Journal</i> , 2016, 48, 808-817.	6.7	75

#	ARTICLE	IF	CITATIONS
253	Global initiative for meticillin-resistant <i>Staphylococcus aureus</i> pneumonia (GLIMP): an international, observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1364-1376.	9.1	109
254	Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 1045-1055.	2.5	6
255	Bronchiectasis in 2016: advances in our understanding. <i>Lancet Respiratory Medicine</i> , the, 2016, 4, 940-941.	10.7	1
256	Empirical Coverage of Methicillin-Resistant <i>Staphylococcus aureus</i> in Community-Acquired Pneumonia: Those Who Do Not Remember the Past Are Doomed to Repeat It. <i>Clinical Infectious Diseases</i> , 2016, 63, 1145-1146.	5.8	12
257	Is it feasible to radiologically monitor the evolution of non- <i>CF</i> bronchiectasis?. <i>Respirology</i> , 2016, 21, 1137-1137.	2.3	2
258	Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. <i>Lancet Respiratory Medicine</i> , the, 2016, 4, 969-979.	10.7	210
259	Cardiovascular autonomic alterations in hospitalized patients with community-acquired pneumonia. <i>Respiratory Research</i> , 2016, 17, 98.	3.6	8
260	Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care. <i>European Respiratory Journal</i> , 2016, 48, 1278-1281.	6.7	7
261	Multidrug-resistant pathogens in patients with pneumonia coming from the community. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 219-226.	2.6	29
262	Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2016, 48, 632-647.	6.7	170
263	Challenges in managing <i>Pseudomonas aeruginosa</i> in non-cystic fibrosis bronchiectasis. <i>Respiratory Medicine</i> , 2016, 117, 179-189.	2.9	70
264	Introducing a new HERMES project on respiratory infections. <i>Breathe</i> , 2016, 12, 5-7.	1.3	6
265	Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees. <i>European Respiratory Journal</i> , 2016, 47, 1345-1347.	6.7	34
266	The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study. <i>Respiratory Medicine</i> , 2016, 112, 51-58.	2.9	27
267	Clinical phenotypes in adult patients with bronchiectasis. <i>European Respiratory Journal</i> , 2016, 47, 1113-1122.	6.7	215
268	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. <i>ERJ Open Research</i> , 2016, 2, 00081-2015.	2.6	133
269	Management of bronchiectasis in Europe: Data from the European bronchiectasis registry (EMBARC). , 2016, , .		2
270	Characteristics of patients with hypoxemic respiratory failure due to pneumonia that respond to the application of a positive end expiratory pressure. , 2016, , .		0



#	ARTICLE	IF	CITATIONS
271	Bronchiectasis in patients with alpha1-antitrypsin deficiency: prevalence and characteristics. , 2016, , .		0
272	Rheumatoid arthritis is a common and important comorbidity in bronchiectasis: Data from the EMBARC European bronchiectasis registry. , 2016, , .		0
273	Exacerbations of bronchiectasis requiring hospitalization; clinical characteristics and outcomes. , 2016, , .		0
274	Corrigendum to "De-escalation therapy among bacteraemic patients with community-acquired pneumonia" [Clin Microbiol Infect 21 (2015) 936.e11-18]. Clinical Microbiology and Infection, 2015, 21, e87.	6.0	1
275	Acute myocardial infarction <i>versus</i> other cardiovascular events in community-acquired pneumonia. ERJ Open Research, 2015, 1, 00020-2015.	2.6	26
276	Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis. BioMed Research International, 2015, 2015, 1-8.	1.9	60
277	Nontuberculous Mycobacteria: Epidemiologic, Mycobacteriologic, and Clinical Aspects. BioMed Research International, 2015, 2015, 1-2.	1.9	11
278	How to choose the duration of antibiotic therapy in patients with pneumonia. Current Opinion in Infectious Diseases, 2015, 28, 177-184.	3.1	17
279	Chronic infection with non-tuberculous mycobacteria in patients with non-CF bronchiectasis: Comparison with other pathogens. International Journal of Mycobacteriology, 2015, 4, 68-69.	0.6	0
280	Delirium symptoms during hospitalization predict long-term mortality in patients with severe pneumonia. Aging Clinical and Experimental Research, 2015, 27, 523-531.	2.9	20
281	Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium. International Journal of Infectious Diseases, 2015, 32, 156-160.	3.3	19
282	Management of bronchiectasis in adults. European Respiratory Journal, 2015, 45, 1446-1462.	6.7	220
283	Challenges in the development of new therapies for bronchiectasis. Expert Opinion on Pharmacotherapy, 2015, 16, 833-850.	1.8	20
284	Towards tuberculosis elimination: an action framework for low-incidence countries. European Respiratory Journal, 2015, 45, 928-952.	6.7	608
285	Chromogranin A levels and mortality in patients with severe sepsis. Biomarkers, 2015, 20, 171-176.	1.9	8
286	Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. Annals of the American Thoracic Society, 2015, 12, 1764-1770.	3.2	233
287	Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response. Infection, 2015, 43, 729-738.	4.7	36
288	A Comprehensive Analysis of the Impact of <i>Pseudomonas aeruginosa</i> Colonisation on Prognosis in Adult Bronchiectasis. Annals of the American Thoracic Society, 2015, 12, 1602-11.	3.2	258

#	ARTICLE	IF	CITATIONS
289	Patients in randomized clinical trials of bronchiectasis are only partially representative of clinical practice: A European cohort study. , 2015, , .		0
290	Heterogeneity in bronchiectasis service provision in Europe: Baseline data from the European bronchiectasis registry (EMBARC). , 2015, , .		1
291	Research priorities in bronchiectasis: A consensus from the European multicentre bronchiectasis audit and research collaboration (EMBARC) study group. , 2015, , .		0
292	Epidemiology of clinical trials in respiratory diseases in Europe and Italy. , 2015, , .		0
293	The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients. PLoS ONE, 2014, 9, e101228.	2.5	79
294	Preventing Arterial Catheter-Associated Bloodstream Infections. Critical Care Medicine, 2014, 42, 1533-1534.	0.9	0
295	Dyspnea in crackling lungs. European Journal of Internal Medicine, 2014, 25, e115-e116.	2.2	0
296	Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases. BMC Pulmonary Medicine, 2014, 14, 194.	2.0	40
297	Cardiac diseases complicating community-acquired pneumonia. Current Opinion in Infectious Diseases, 2014, 27, 295-301.	3.1	41
298	Influenza A/H1N1 Severe Pneumonia: Novel Morphocytological Findings in Bronchoalveolar Lavage. Interdisciplinary Perspectives on Infectious Diseases, 2014, 2014, 1-4.	1.4	4
299	Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respiratory Research, 2014, 15, 27.	3.6	39
300	The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: Results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine, 2014, 32, 2198-2203.	3.8	42
301	Management of nontuberculous mycobacterial infection in the elderly. European Journal of Internal Medicine, 2014, 25, 356-363.	2.2	44
302	Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia. Inflammation, 2014, 37, 1158-1166.	3.8	51
303	The management of community-acquired pneumonia in the elderly. European Journal of Internal Medicine, 2014, 25, 312-319.	2.2	87
304	Editorial Commentary: Healthcare-Associated Pneumonia: Where Do We Go Next?. Clinical Infectious Diseases, 2014, 58, 340-341.	5.8	6
305	COPD and Bronchiectasis: Phenotype, Endotype or Co-morbidity?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 603-604.	1.6	40
306	The role of vaccination in preventing pneumococcal disease in adults. Clinical Microbiology and Infection, 2014, 20, 52-58.	6.0	46

#	ARTICLE	IF	CITATIONS
307	Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia. <i>Intensive Care Medicine</i> , 2014, 40, 942-949.	8.2	152
308	Predicting <i>Mycobacterium tuberculosis</i> in patients with community-acquired pneumonia. <i>European Respiratory Journal</i> , 2014, 43, 178-184.	6.7	23
309	The Bronchiectasis Severity Index. An International Derivation and Validation Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 576-585.	5.6	747
310	Is it time for a "pneumo-geriatrician" for frail old patients with respiratory diseases?. <i>European Journal of Internal Medicine</i> , 2014, 25, 303.	2.2	1
311	Pneumococcal Vaccine and Patients with Pulmonary Diseases. <i>American Journal of Medicine</i> , 2014, 127, 886.e1-886.e8.	1.5	28
312	Geriatric multidimensional assessment for elderly patients with acute respiratory diseases. <i>European Journal of Internal Medicine</i> , 2014, 25, 304-311.	2.2	5
313	Validation of a Disease Specific Severity Index for Non-Cystic Fibrosis Bronchiectasis: The BSI Index. <i>Chest</i> , 2014, 145, 428A.	0.8	0
314	Antiplatelets Improve Survival Among Critically Ill Mechanically Ventilated Patients. <i>Chest</i> , 2014, 146, 500A.	0.8	1
315	Early outcomes in CAP: clinical stability, clinical failure and nonresolving pneumonia. , 2014, , 205-218.		0
316	Clustering Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients According to Clinical Features. <i>Chest</i> , 2014, 146, 718A.	0.8	0
317	Microbiological Diagnosis and Antibiotic Therapy in Patients with Community-Acquired Pneumonia and Acute COPD Exacerbation in Daily Clinical Practice: Comparison to Current Guidelines. <i>Lung</i> , 2013, 191, 239-246.	3.3	22
318	Hospital Admission Decision for Patients with Community-Acquired Pneumonia. <i>Current Infectious Disease Reports</i> , 2013, 15, 167-176.	3.0	13
319	Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes. <i>International Journal of Infectious Diseases</i> , 2013, 17, e293-e298.	3.3	27
320	Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. <i>International Journal of Infectious Diseases</i> , 2013, 17, e76-e83.	3.3	163
321	Diaphragm ultrasonography in the management of patients with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 154-156.	1.7	12
322	Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: Table A1. <i>Thorax</i> , 2013, 68, 997-999.	5.6	129
323	A 61-year-old female with chronic cough and purulent sputum. <i>European Respiratory Journal</i> , 2013, 41, 472-474.	6.7	0
324	TB elimination: a dream or a reality? Key lessons from the ERS external course in Dubrovnik, Croatia. <i>Breathe</i> , 2013, 9, 458-461.	1.3	0

#	ARTICLE	IF	CITATIONS
325	The Changing Microbiologic Epidemiology of Community-Acquired Pneumonia. <i>Postgraduate Medicine</i> , 2013, 125, 31-42.	2.0	27
326	Criteria for clinical stability in hospitalised patients with community-acquired pneumonia. <i>European Respiratory Journal</i> , 2013, 42, 742-749.	6.7	34
327	Idiopathic Bronchiectasis Less Common Than Predicted: Quality Improvement Project. <i>Chest</i> , 2013, 144, 586A.	0.8	0
328	Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia. <i>Chest</i> , 2013, 144, 999-1007.	0.8	162
329	Impact of exacerbations in the natural course of COPD. , 2013, , 84-95.		0
330	Clinical Stability versus Clinical Failure in Patients with Community-Acquired Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 284-291.	2.1	18
331	Stratifying Risk Factors for Multidrug-Resistant Pathogens in Hospitalized Patients Coming From the Community With Pneumonia. <i>Clinical Infectious Diseases</i> , 2012, 54, 470-478.	5.8	191
332	Pneumonia in the Community Caused by Multidrug-Resistant Organisms: Keep Working on Probabilistic Scores. <i>Clinical Infectious Diseases</i> , 2012, 54, 1519-1520.	5.8	9
333	Should Health Care Systems and Health Care Providers Implement a New Pathway for Hospitalized Patients With Community-Acquired Pneumonia?. <i>Archives of Internal Medicine</i> , 2012, 172, 1771.	3.8	0
334	Compliance with anti-H1N1 vaccine among healthcare workers and general population. <i>Clinical Microbiology and Infection</i> , 2012, 18, 37-41.	6.0	49
335	The role of lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2012, 23, 391-397.	2.2	84
336	The role of biomarkers in low respiratory tract infections. <i>European Journal of Internal Medicine</i> , 2012, 23, 429-435.	2.2	14
337	The management of patients with community-acquired pneumonia beyond antibiotic therapy. <i>European Journal of Internal Medicine</i> , 2012, 23, 389-390.	2.2	3
338	Lung Ultrasound in the Diagnosis and Follow-up of Community-Acquired Pneumonia. <i>Chest</i> , 2012, 142, 965-972.	0.8	339
339	Antibiotics as immunomodulant agents in COPD. <i>Current Opinion in Pharmacology</i> , 2012, 12, 293-299.	3.5	26
340	Where are the acutely ill best cared for and who should look after them?. <i>European Journal of Internal Medicine</i> , 2011, 22, 323.	2.2	1
341	Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia. <i>Respiratory Medicine</i> , 2011, 105, 1732-1738.	2.9	35
342	Noninvasive ventilation or continuous positive airway pressure in pulmonary edema patients with respiratory acidosis? Look at the bicarbonates. <i>Intensive Care Medicine</i> , 2011, 37, 2050-2051.	8.2	3

#	ARTICLE	IF	CITATIONS
343	Early application of non-invasive continuous positive airway pressure in acute respiratory distress syndrome due to a drug overdose: a case report. <i>Internal and Emergency Medicine</i> , 2011, 6, 275-276.	2.0	3
344	Association Between Time to Clinical Stability and Outcomes After Discharge in Hospitalized Patients With Community-Acquired Pneumonia. <i>Chest</i> , 2011, 140, 482-488.	0.8	41
345	Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 542-546.	1.2	55
346	Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. <i>European Respiratory Journal</i> , 2010, 36, 128-134.	6.7	59
347	Thrombocytopenia and Thrombocytosis at Time of Hospitalization Predict Mortality in Patients With Community-Acquired Pneumonia. <i>Chest</i> , 2010, 137, 416-420.	0.8	129
348	Helmet Continuous Positive Airway Pressure vs Oxygen Therapy To Improve Oxygenation in Community-Acquired Pneumonia. <i>Chest</i> , 2010, 138, 114-120.	0.8	137
349	Thrombocytosis in Patients With Severe Community-Acquired Pneumonia: Response. <i>Chest</i> , 2010, 138, 1279-1280.	0.8	1
350	Acidemia does not affect outcomes of patients with acute cardiogenic pulmonary edema treated with continuous positive airway pressure. <i>Critical Care</i> , 2010, 14, R196.	5.8	16
351	Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. <i>Pulmonary Pharmacology and Therapeutics</i> , 2010, 23, 200-207.	2.6	66
352	The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia. <i>European Respiratory Journal</i> , 2009, 33, 142-147.	6.7	12
353	Usefulness of simplified acute physiology score II in predicting mortality in patients admitted to an emergency medicine ward. <i>Internal and Emergency Medicine</i> , 2009, 4, 241-247.	2.0	10
354	Acute effects of positive end-expiratory pressure on left ventricle diastolic function in healthy subjects. <i>Internal and Emergency Medicine</i> , 2009, 4, 249-254.	2.0	5
355	Mortality in acute cardiogenic pulmonary edema treated with continuous positive airway pressure. <i>Intensive Care Medicine</i> , 2009, 35, 299-305.	8.2	16
356	Bronchiectasis: an update. <i>Clinical Respiratory Journal</i> , 2009, 3, 126-134.	1.6	15
357	<i>Chlamydomphila pneumoniae</i> . <i>Clinical Microbiology and Infection</i> , 2009, 15, 29-35.	6.0	110
358	Severe asthma exacerbation: role of acute <i>Chlamydomphila pneumoniae</i> and <i>Mycoplasma pneumoniae</i> infection. <i>Respiratory Research</i> , 2008, 9, 48.	3.6	53
359	Acute Myocardial Infarction in Hospitalized Patients with Community-Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2008, 47, 182-187.	5.8	166
360	Impact of neutrophil function on outcomes of community-acquired pneumonia in patients with cancer. <i>European Respiratory Review</i> , 2008, 17, 83-85.	7.1	0

#	ARTICLE	IF	CITATIONS
361	Incidence, Etiology, Timing, and Risk Factors for Clinical Failure in Hospitalized Patients With Community-Acquired Pneumonia. <i>Chest</i> , 2008, 134, 955-962.	0.8	112
362	Chlamydia Pneumoniae and Acute Aortic Syndrome: A Call for a Multi-Institutional Study. <i>Monaldi Archives for Chest Disease</i> , 2008, 70, 68-70.	0.6	3
363	100 years of respiratory medicine: Pneumonia. <i>Respiratory Medicine</i> , 2007, 101, 875-881.	2.9	11
364	Antibiotic therapy and prophylaxis in COPD. <i>Respiratory Medicine: COPD Update</i> , 2007, 2, 124-132.	0.0	4
365	<i>Chlamydia pneumoniae</i> induces a sustained airway hyperresponsiveness and inflammation in mice. <i>Respiratory Research</i> , 2007, 8, 83.	3.6	25
366	Mixed community-acquired lower respiratory tract infections. <i>Current Infectious Disease Reports</i> , 2007, 9, 14-20.	3.0	8
367	Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis. <i>International Journal of COPD</i> , 2007, 2, 27-31.	2.3	4
368	Clinical applications of azithromycin microspheres in respiratory tract infections. <i>International Journal of Nanomedicine</i> , 2007, 2, 551-9.	6.7	13
369	Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. <i>Pulmonary Pharmacology and Therapeutics</i> , 2006, 19, 11-19.	2.6	13
370	Telithromycin in lower respiratory tract infections. <i>Future Microbiology</i> , 2006, 1, 7-16.	2.0	4
371	A 13-year-old female with shortness of breath and pleuritic chest pain. <i>European Respiratory Journal</i> , 2006, 28, 876-882.	6.7	8
372	Hospital-acquired pneumonia. <i>Breathe</i> , 2005, 1, 296-301.	1.3	4
373	<i>Chlamydia pneumoniae</i> and <i>Mycoplasma pneumoniae</i> . <i>Seminars in Respiratory and Critical Care Medicine</i> , 2005, 26, 617-624.	2.1	35
374	Azithromycin and lower respiratory tract infections. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2335-2351.	1.8	14
375	Strategic Targets of Essential Host-Pathogen Interactions. <i>Respiration</i> , 2005, 72, 9-25.	2.6	34
376	Neutrophil Extracellular Traps are Increased in Severe Bronchiectasis and Reduced by Long-Term Azithromycin Treatment. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
377	Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. <i>Multidisciplinary Respiratory Medicine</i> , 0, 13, .	1.5	2
378	Identifying patients with pneumonia due to MDR organisms coming from the community. , 0, , 97-110.		0

#	ARTICLE	IF	CITATIONS
379	Site of care and multidisciplinary approach. , 0, , 353-370.		2